BRAF and melanoma: Melanoma patients, despite having BRAF mutation, show varied responses to vemurafenib; however, no studies to date have analyzed the molecular relationships between vemurafenib tolerance thresholds and the specific metabolic pathways utilized to ensure melanoma survival.